JP2014516538A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516538A5
JP2014516538A5 JP2014512143A JP2014512143A JP2014516538A5 JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5 JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5
Authority
JP
Japan
Prior art keywords
antigen
cells
patient
full
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014512143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/039605 external-priority patent/WO2012162620A1/en
Publication of JP2014516538A publication Critical patent/JP2014516538A/ja
Publication of JP2014516538A5 publication Critical patent/JP2014516538A5/ja
Pending legal-status Critical Current

Links

JP2014512143A 2011-05-26 2012-05-25 調節された免疫優勢療法 Pending JP2014516538A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490505P 2011-05-26 2011-05-26
US61/490,505 2011-05-26
PCT/US2012/039605 WO2012162620A1 (en) 2011-05-26 2012-05-25 Modulated immunodominance therapy

Publications (2)

Publication Number Publication Date
JP2014516538A JP2014516538A (ja) 2014-07-17
JP2014516538A5 true JP2014516538A5 (https=) 2015-07-02

Family

ID=46208182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512143A Pending JP2014516538A (ja) 2011-05-26 2012-05-25 調節された免疫優勢療法

Country Status (12)

Country Link
US (8) US20140099341A1 (https=)
EP (2) EP2714072A1 (https=)
JP (1) JP2014516538A (https=)
KR (2) KR20160104753A (https=)
CN (2) CN103906531A (https=)
AU (4) AU2012258603A1 (https=)
CA (1) CA2874431A1 (https=)
HK (1) HK1199404A1 (https=)
RU (1) RU2013157923A (https=)
SG (2) SG10201604236RA (https=)
TW (3) TW202321442A (https=)
WO (1) WO2012162620A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013959A (es) * 2016-05-25 2019-08-22 Council Queensland Inst Medical Res Metodos para tratar enfermedad autoinmune usando celulas t alogenicas.
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
KR20190037243A (ko) * 2016-06-28 2019-04-05 지니우스 바이오테크놀로지 인코포레이티드 면역치료를 위한 티 세포 조성물
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504799A (ja) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
WO2004042041A1 (en) 2002-11-07 2004-05-21 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic t-lymphoctyes
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
MX2007015933A (es) * 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses

Similar Documents

Publication Publication Date Title
Abbott et al. Cancer and the immune system: the history and background of immunotherapy
Su et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models
Maue et al. An ESAT-6: CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis
JP2014516538A5 (https=)
Tian et al. Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model
JP2005523277A (ja) 癌の治療
Herrada et al. Harnessing DNA-induced immune responses for improving cancer vaccines
Lim et al. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
Bhattacharyya et al. Immunological interactions in radiotherapy—opening a new window of opportunity
Becker et al. Skin vaccination with live virus vectored microneedle arrays induce long lived CD8+ T cell memory
Freitas-Silva et al. Dendritic cell-based approaches in the fight against diseases
JP2018016651A (ja) 能動免疫療法のためのＴｈ１ワクチン接種プライミング
Lu et al. Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model
Grasse et al. GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
Holmes et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I‐01 and I‐02
Nguyen et al. Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Brody et al. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
Dai et al. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice
RU2013157923A (ru) Терапия на основе модулирования иммунодоминантности
US20110319871A1 (en) Infectious disease cellular immunotherapy
WO2006033991A1 (en) Dendritic cell tumor injection (dcti) therapy
Pawelec et al. Impact of aging on cancer immunity and immunotherapy
Locy et al. Dendritic cells: the tools for cancer treatment
Zhang et al. Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus
Smyth et al. Repetitive peptide boosting progressively enhances functional memory CTLs